Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Atricure Inc (ATRC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 663,723
  • Shares Outstanding, K 33,950
  • Annual Sales, $ 155,110 K
  • Annual Income, $ -33,340 K
  • 36-Month Beta 0.69
  • Price/Sales 4.31
  • Price/Cash Flow 0.00
  • Price/Book 3.89

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.02 +8.49%
on 03/23/17
19.82 -1.36%
on 04/19/17
+1.07 (+5.79%)
since 03/21/17
3-Month
14.78 +32.27%
on 01/23/17
19.82 -1.36%
on 04/19/17
+4.45 (+29.47%)
since 01/20/17
52-Week
13.44 +45.46%
on 05/12/16
20.40 -4.17%
on 11/15/16
+2.86 (+17.14%)
since 04/21/16

Most Recent Stories

More News
AtriCure to Announce First Quarter 2017 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release...

ATRC : 19.55 (-0.71%)
AtriCure Names Two New Members to its Board of Directors

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Regina Groves...

SPNC : 27.35 (-3.36%)
PJC : 58.90 (-1.26%)
ATRC : 19.55 (-0.71%)
MDT : 80.48 (-0.67%)
AtriCure to Present at the Needham & Company's 16th Annual Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present...

ATRC : 19.55 (-0.71%)
AtriCure Announces hiring of Senior Vice President of Clinical, Regulatory, and Scientific Affairs

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Vinayak (Vini)...

STJ : 80.82 (+0.16%)
ATRC : 19.55 (-0.71%)
AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2016

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial...

ATRC : 19.55 (-0.71%)
AtriCure to Present at the 35th Annual JP Morgan Healthcare Conference

AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present...

ATRC : 19.55 (-0.71%)
AtriCure Names Sven Wehrwein to its Board of Directors

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Sven Wehrwein...

ATRC : 19.55 (-0.71%)
PRLB : 50.05 (-4.76%)
AtriCure to Present at the Piper Jaffray 28th Annual Healthcare Conference

AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present...

ATRC : 19.55 (-0.71%)
AtriCure (ATRC): Moving Average Crossover Alert

Are you a technical investor? If so, it may be time to consider AtriCure, Inc. (ATRC) for your portfolio

ATRC : 19.55 (-0.71%)
AtriCure Announces Approval for the cryoICE(TM) Platform in Japan

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received...

ATRC : 19.55 (-0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as...

See More

Support & Resistance

2nd Resistance Point 19.87
1st Resistance Point 19.71
Last Price 19.55
1st Support Level 19.43
2nd Support Level 19.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.